EMD Millipore, the Life Science business of Merck KGaA of Darmstadt, Germany, today announced the launch of its Cellvento^TM CHO platform of cell culture media and companion feed formulations for batch, fed-batch and perfusion applications. Available in liquid and powder form, the chemically defined, non-animal-origin media deliver superior cell growth and productivity for various CHO cell types used in biopharmaceutical development and manufacturing.

The Cellvento^TM CHO platform includes cell line and process-specific media and feed compositions, allowing selection of the optimal media formulation for a given application. The range of products also offers customers the flexibility to choose the most suitable product to achieve the best possible performance results for their specific cell line.

The platform provides a variety of formulations designed to meet the needs of CHO-S, CHO-DHFR negative and CHO-K1 suspension cell types. All formulations offer excellent powder homogeneity and consistency, resulting in strong lot-to-lot reproducibility. The media are supported by comprehensive regulatory information on their manufacture, characterization and control.

“Biopharmaceutical manufacturers require cell culture media that will deliver the most robust product yield, quality and consistency,” said Andrew Bulpin, executive vice president of EMD Millipore, Process Solutions Business Area. “The Cellvento^TM CHO platform offers a variety of formulations, all backed by EMD Millipore’s strong chemical, raw material and regulatory expertise. This range of options ensures customers have the flexibility to select the best media for their specific process, optimizing their production and ultimately accelerating time to market.”

The Cellvento^TM CHO platform includes the following media:

The production media all have companion feed formulations to extend the cell production phase and maximize yields.

For more information about the Cellvento^TM CHO platform, please visit www.emdmillipore.com/cellvento.